PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 3, 2007, Pages 149-155

  Quéméneur, Thomas ^a   Martin Nizard, Françoise ^b   Kandoussi, Abdelmejid ^b   Kyndt, Xavier ^a   Vanhille, Philippe ^a   Hachulla, Eric ^c   Hatron, Pierre Yves ^c   Fruchart, Jean Charles ^b   Duriez, Patrick ^d   Lambert, Marc ^c  

^a Hospital of Valenciennes   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

atherosclerosis; inflammation; oxidized LDL; paraoxonase; vasculitis

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MALE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC VASCULITIS;

AGED; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; VASCULITIS;

EID: 36348998621     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.03.002     Document Type: Article

References (47)

1. Cupps T.R., and Fauci A.S. The vasculitic syndromes. Adv Intern Med 27 (1982) 315-344
2. Salisbury E.M., McLaren J.S., Jayne D.R.W., and Luqmani R.A. Cardiovascular disease incidence and risks factors in ANCA-associated primary systemic vasculitis (AASV). Arthritis Rheum 48 Suppl (2003) 207
3. Conn D.L. Update on systemic necrotizing vasculitis. Mayo Clin Proc 64 (1989) 535-543
4. Somer T. Thrombo-embolic and vascular complications in vasculitis syndromes. Eur Heart J 14 Suppl K (1993) 24-29
5. Uddhammar A., Eriksson A.L., Nystrom L., Stenling R., and Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 29 (2002) 737-742
6. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu's arteritis. Ann Intern Med 120 (1994) 919-929
7. Forstot J.Z., Overlie P.A., Neufeld G.K., Harmon C.E., and Forstot S.L. Cardiac complications of Wegener's granulomatosis: a case report of complete heart block and review of the literature. Semin Arthritis Rheum 10 (1980) 148-154
8. Qiao J.H., Castellani L.W., Fishbein M.C., and Lusis A.J. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb 13 (1993) 932-943
9. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
10. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86 (1989) 1372-1376
11. Wang C.R., Liu M.F., Tsai R.T., Chuang C.Y., and Chen C.Y. Circulating intercellular adhesion molecules-1 and autoantibodies including anti-endothelial cell, anti-cardiolipin, and anti-neutrophil cytoplasma antibodies in patients with vasculitis. Clin Rheumatol 12 (1993) 375-380
12. Swets B.P., Brouwer D.A., and Tervaert J.W. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 124 (2001) 163-167
13. Mackness B., Durrington P.N., and Mackness M.I. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 13 (2002) 357-362
14. Furlong C.E., Cole T.B., Jarvik G.P., and Costa L.G. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3 (2002) 341-348
15. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
16. Graner M., James R.W., Kahri J., Nieminen M.S., Syvanne M., and Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 47 (2006) 2429-2435
17. Leopold J.A., and Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 1332-1340
18. Lambert M., Boullier A., Hachulla E., Fruchart J.C., Teissier E., Hatron P.Y., et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 9 (2000) 299-300
19. Delgado Alves J., Ames P.R., Donohue S., Stanyer L., Nouroz-Sadeh J., Ravirajan C., et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46 (2002) 2686-2694
20. Havel R.J. Rational for cholesterol lowering. Am J Med 87 Suppl (1989) 2S-4S
21. Palinski W., Yla-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low-density lipoprotein. Arteriosclerosis 10 (1990) 325-335
22. Esterbauer H., Dieber-Rotheneder M., Waeg G., Striegl G., and Jurgens G. Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol 3 (1990) 77-92
23. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Annal Biochem 83 (1977) 346-356
24. Boullier A., Hamon M., Walters-Laporte E., Martin-Nizart F., Mackereel R., Fruchart J.C., et al. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low-density lipoproteins in patients with coronary artery disease. Clin Chim Acta 238 (1995) 1-10
25. Eckerson H.W., Romson J., Wyte C., and La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35 (1983) 214-227
26. Dati F., Schumann G., Thomas L., Aguzzi F., Baudner S., Bienvenu J., et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 34 (1996) 517-520
27. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 (2001) 418-425
28. Bergmark C., Wu R., de Faire U., Lefvert A.K., and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15 (1995) 441-445
29. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
30. Gallou G.R.A., Campion L., Allannic H., Legras B., and Cloarec L. Susceptibility of LDL to lipid peroxidation in non-insulin-dependent diabetes mellitus with or without macroangiopathy. Ann Biol Clin (Paris) 52 (1994) 695-699
31. Albert M.A., Staggers J., Chew P., Ridker P.M., and PRINCE Investigators. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 141 (2001) 893-898
32. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275 (2000) 36703-36707
33. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., and Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
34. Ames P.R., Margarita A., Delgado Alves J., Tommasino C., Iannaccone L., and Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima-media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11 (2002) 208-214
35. Li X.C., Chen P., and Zhu Y.L. Correlation of autoantibodies against oxidized low-density lipoprotein and its immune complex with coronary artery disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 31 (2002) 321-325
36. Khovidhunkit W., Memon R.A., Feingold K.R., and Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 181 Suppl 3 (2000) S462-S472
37. Erren M., Reinecke H., Junker R., Fobker M., Schulte H., Schurek J.O., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19 (1999) 2355-2363
38. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
39. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7 (1996) 69-76
40. Harper L., Nuttall S.L., Martin U., and Savage C.O. Adjuvant treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis with vitamins E and C reduces superoxide production by neutrophils. Rheumatology 41 (2002) 274-278
41. Lonn E., Yusuf S., Hoogwerf B., Pogue J., Yi Q., Zinman B., et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25 (2002) 1919-1927
42. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., and Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361 (2003) 2017-2023
43. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
44. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6 (2000) 1399-1402
45. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
46. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B., Stott D.J., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
47. Pineda Torra I., Gervois P., and Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10 (1999) 151-159